Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury

Yuri Ikeda-Matsuo1, Azusa Ota, Tetsuya Fukada

  • 1Laboratory of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo 108-8641, Japan. matsuoy@pharm.kitasato-u.ac.jp

Insights

Microsomal prostaglandin E synthase 1 (mPGES-1) promotes brain damage after stroke. Inhibiting mPGES-1 reduces stroke severity and neurological deficits, highlighting it as a potential therapeutic target for stroke treatment.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Prostaglandin E(2) (PGE(2)) plays a controversial role in neuronal survival following ischemic stroke.
  • Its synthesis and accumulation increase at lesion sites in rodent models.

Purpose of the Study:

  • To investigate the role of microsomal prostaglandin E synthase 1 (mPGES-1) in post-ischemic neuronal survival and neurological dysfunction.
  • To evaluate mPGES-1 as a potential therapeutic target for stroke.

Main Methods:

  • Utilized mPGES-1 knockout (KO) mice and wild-type (WT) mice subjected to transient focal ischemia.
  • Assessed infarction volume, edema, apoptotic cell death, caspase-3 activation, and behavioral neurological deficits.
  • Administered intracerebroventricular injection of PGE(2) in KO mice.

Main Results:

  • mPGES-1 was induced in neurons, microglia, and endothelial cells post-ischemia.
  • mPGES-1 KO mice exhibited reduced infarction, edema, apoptosis, and caspase-3 activation compared to WT mice.
  • KO mice showed significantly improved neurological function, which was reversed by exogenous PGE(2) administration.

Conclusions:

  • mPGES-1 is a critical determinant of post-ischemic neurological dysfunction.
  • Targeting mPGES-1 offers a promising therapeutic strategy for stroke treatment.